Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
No, Tricare is not the same as Medicare
Correia-Rodrigues A, Ribeiro-Rodrigues T, Goncalves L, Almeida JP, Ferreira MJ, Girao H
Research applications In-vitro modeling of synergistic GHRH/GHRP receptor cross-talk Pre-clinical study of pulsatile GH-secretagogue dynamics Comparative receptor-pathway research (cAMP vs calcium convergence) Reference standard for analytical characterization of blended preparations Key facts Combines a GHRH-receptor analog with a selective GHS-R1a agonist Nominal 5mg + 5mg per-component loading per vial Components act through mechanistically independent, convergent pathways Supplied as a co-lyophilized research powder for in-vitro use Product specifications Class: GHRH analog + GHRP/ghrelin-receptor agonist research blend Also known as: Mod-GRF + Ipamorelin blend Form: Lyophilized powder vial Purity: 99% (HPLC verified) Testing: Independent third-party HPLC + mass spectrometry Documentation: Certificate of analysis per batch Storage: Store lyophilized at -20C
Protective interventions such as NAC, metformin, or HO-1 modulation have shown protective effects in preclinical models by enhancing antioxidant defense (e.g., GPX4, Nrf2, HO-1) and reducing follicular loss (Zhang S
Conclusions Our work demonstrates that the efficiency of GST-mediated enzymatic conjugation to GSH, which functions in choroid plexuses, can be enhanced by activating the Nrf2 signaling pathway during early postnatal development
9 , e3353 (2019)
US$ 26.01
US$ 23.87
US$ 23.67
US$ 24.46
